Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

denosumab

denosumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Jubbonti SOLUTION, SUBCUTANEOUS 60 mg/mL    
Ospomyv SOLUTION, SUBCUTANEOUS 60 mg/mL    
Prolia SOLUTION, SUBCUTANEOUS 60 mg/mL    
Stoboclo SOLUTION, SUBCUTANEOUS 60 mg/mL    
Conexxence SOLUTION, SUBCUTANEOUS 120 mg/1.7 mL    
Xgeva SOLUTION, SUBCUTANEOUS 120 mg/1.7 mL      
VIEW MORE Bone Resorption Inhibitors
CLASS
922400
Comments:

Prolia medication guide

Prolia, Xgeva, and all denosumab (Prolia) biosimilars approved by the Committee are restricted to the hospital outpatient setting.

Ospomyv, Stoboclo, Conexxence, and Jubbonti are biosimilars to Prolia. The denosumab (Prolia) biosimilars approved by the Committee are classified as therapeutically equivalent and interchangeable to Prolia and other denosumab biosimilars for the FDA approved indications and literature supported off-label uses. The most cost-effective agent may be used in a given patient, situation, or time period.

Inpatient consideration, denosumab use in hypercalcemia urgency (not hypercalcemia of malignancy):  - Currently, little reliable information is available regarding the use of denosumab for hypercalcemia urgency related to parathyroid hormone abnormality.  This medication is relatively long acting, so clinical response could be delayed  (up to a week or longer for time to response and complete response seen out to 3+ weeks).  There is currently no criteria set or protocol for using denosumab in hypercalcemia urgency at Huntsville Hospital; use should be evaluated on a case by case basis. (Drug Info statement December 2022)

Reviewed: August 24, 2010 (Prolia) and March 22, 2011 (Xgeva), June 2025 (Ospomyy,Stoboclo,Conexxence, and Jubbonti)

REMS (Prolia): View FDA REMS Info

Last updated: Jun. 30, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved